Jannah Zulkefli

Jannah Zulkefli

Auto-generated profile, based on publicly available information

Jannah Zulkefli

The Mah Pooi Soo & Tan Chin Nam Centre of Parkinson's and Related Disorders, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Parasite
Verified
Journal Article
Open access
PDF file
NYNoorazian Md Yusuf
Noorazian Md Yusuf
JZJannah Zulkefli
Jannah Zulkefli
AJAdela Ida Jiram
Adela Ida Jiram
IVIndra Vythilingam
Indra Vythilingam
SHShamilah Hisam
Shamilah Hisam
LSLokman Hakim Sulaiman
Lokman Hakim Sulaiman
Macaques, Macaca fascicularis, are a known reservoir of Plasmodium knowlesi, the agent of simian malaria which is the predominant zoonotic species affecting humans in Malaysia and other Southeast Asian countries. Recently, a naturally acquired human infection of another simian malaria parasite, P. cynomolgi has been reported. Thus, it is crucial to study the distribution of simian Plasmodium infections with particular attention to the macaques. Four hundred and nineteen (419) long-tailed macaques (Macaca fascicularis) were trapped in selected areas where human cases of P. knowlesi and P. cynomolgi have been reported. Nested polymerase chain reaction (PCR) was conducted to identify the Plasmodium spp., and circumsporozoite protein (CSP) genes of P. knowlesi samples were sequenced. Plasmodium cynomolgi infection was shown to be the most prevalent among the macaque population (68.4%). Although 50.6% of analyzed samples contained single infections either with P. knowlesi, P. cynomolgi, P. inui, P. coatneyi, or P. fieldi, mixed infections with double, triple, quadruple, and all 5 species were also detected. Infection with P. cynomolgi and P. knowlesi were the highest among Malaysian macaques in areas where humans and macaques are in close contact. The risk of zoonotic infection in these areas needs to be addressed since the number of zoonotic malaria cases is on the rise. With the elimination of human malaria, the risk of humans being infected with simian malaria is very high and steps should be taken to mitigate this issue.

23 February 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SLShen-Yang Lim
Shen-Yang Lim
TTTzi Shin Toh
Tzi Shin Toh
JHJia Wei Hor
Jia Wei Hor
JLJia Lun Lim
Jia Lun Lim
LLLei Cheng Lit
Lei Cheng Lit
ATAi Huey Tan
Ai Huey Tan
LRRK2-related Parkinson’s disease (LRRK2-PD) is the most frequent form of monogenic PD worldwide, with important therapeutic opportunities, exemplified by the advancement in LRRK2 kinase inhibition studies/trials. However, many LRRK2 variants, especially those found in underrepresented populations, remain classified as variants of uncertain significance (VUS). Leveraging on Malaysian, Singaporean, and mainland Chinese PD datasets (n = 4901), we describe 12 Chinese-ancestry patients harboring the LRRK2 p.Arg1067Gln variant, more than doubling the number of previously reported cases (total n = 23, 87% East Asian, mean age of onset: 53.9 years). We determine that this variant is enriched in East Asian PD patients compared to population controls (OR = 8.0, 95% CI: 3.0–20.9), and provide supportive data for its co-segregation with PD, albeit with incomplete penetrance. Utilizing established experimental workflows, this variant showed increased LRRK2 kinase activity, by ~2-fold compared to wildtype and higher than the p.Gly2019Ser variant. Taken together, p.Arg1067Gln should be reclassified from a VUS to pathogenic for causing LRRK2-PD.

30 April 2024 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
SLShen-Yang Lim
Shen-Yang Lim
ATAi Huey Tan
Ai Huey Tan
JFJia Nee Foo
Jia Nee Foo
YTYi Jayne Tan
Yi Jayne Tan
ECElaine Gy Chew
Elaine Gy Chew
ANAdeline Sl Ng
Adeline Sl Ng
Lysosomal dysfunction plays an important role in neurodegenerative diseases, including Parkinson’s disease (PD) and possibly Parkinson-plus syndromes such as progressive supranuclear palsy (PSP). This role is exemplified by the involvement of variants in the GBA1 gene, which results in a deficiency of the lysosomal enzyme glucocerebrosidase and is the most frequently identified genetic factor underlying PD worldwide. Pathogenic variants in the SMPD1 gene are a recessive cause of Niemann–Pick disease types A and B. Here, we provide the first report on an association between a loss-of-function variant in the SMPD1 gene present in a heterozygous state (p.Pro332Arg/p.P332R, which is known to result in reduced lysosomal acid sphingomyelinase activity), with PSP-Richardson syndrome in three unrelated patients of Chinese ancestry.

20 April 2026 in Movement Disorders
Verified
Journal Article
Open access
TTTzi Shin Toh
Tzi Shin Toh
LLLei Cheng Lit
Lei Cheng Lit
SLShen‐Yang Lim
Shen‐Yang Lim
JHJia Wei Hor
Jia Wei Hor
CLChoey Yee Lew
Choey Yee Lew
ATAi Huey Tan
Ai Huey Tan
Background: Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials. Objective: The aim of this study was to characterize ex vivo LRRK2 activation status and its clinical correlates in patients with PD carrying LRRK2 p.G2385R and/or p.R1628P variants and in patients with idiopathic PD (iPD). Methods: We recruited 242 participants: patients with PD carrying LRRK2 p.G2385R (PD‐G2385R; n = 57), p.R1628P (PD‐R1628P; n = 61), or both (n = 5); patients with iPD (n = 61); and healthy control subjects (HCs; n = 58). Monocyte LRRK2 activity markers (pRab10 Thr73 and pLRRK2 Ser935 ) were analyzed using multiplexed quantitative immunoblotting. Clinical severity was assessed using the International Parkinson and Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Clinical Impression of Severity Index for PD, and Montreal Cognitive Assessment. Results: Compared with HCs, pRab10 Thr73 was elevated (indicative of LRRK2 kinase hyperactivation) in PD‐G2385R (~1.2‐fold, P = 0.011) and in double‐variant carriers (~2.8‐fold, P = 0.008), but not in PD‐R1628P or iPD. Inversely correlated with pRab10 Thr73 ( r s = −0.611, P < 0.001), pLRRK2 Ser935 was reduced (indicative of a more active LRRK2 conformation) in all PD subgroups (lowest in double‐variant carriers). All double‐variant carriers, the majority of single‐variant carriers, and one‐third of participants with iPD had pRab10 Thr73 greater than the control median. Higher pRab10 Thr73 correlated with better cognition. Conclusions: LRRK2 kinase activity is enhanced in patients with PD carrying LRRK2 p.G2385R, with further elevation observed in a small group of double‐variant carriers. Elevated kinase activity in a subset of iPD underscores the relevance of LRRK2 signaling and therapeutics beyond coding variants. The observed interindividual variability indicates additional genetic or environmental modifiers and highlights the need for biochemical stratification beyond genotyping in future LRRK2 trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

25 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TTTzi Shin Toh
Tzi Shin Toh
LLLei Cheng Lit
Lei Cheng Lit
SLShen-Yang Lim
Shen-Yang Lim
JHJia Wei Hor
Jia Wei Hor
CLChoey Yee Lew
Choey Yee Lew
ATAi Huey Tan
Ai Huey Tan
Importance: LRRK2 kinase inhibition is one of the most promising therapeutic strategies in Parkinson’s disease (PD), yet understanding of kinase activity in the Asian-prevalent p.G2385R and p.R1628P variants, each affecting 5–10% of PD patients, remains limited. Development of patient stratification and target engagement markers applicable across global cohorts is an urgent priority. Objective: To investigate pRab10 Thr73 phosphorylation and pLRRK2 Ser935 dephosphorylation as markers of in vivo LRRK2 activation status in human monocytes from manifesting carriers of p.G2385R and p.R1628P, and idiopathic PD (iPD), with clinical correlations. Design: Cross-sectional, observational study conducted between 2021 to 2024. Setting: Multi-ethnic Asian cohort from two quaternary hospitals in Malaysia. Participants: This study included 242 participants, consisting of PD-G2385R ( n =57), PD-R1628P ( n =61), PD-G2385R+R1628P ( n =5), as well as age- and sex-matched iPD ( n =61) and healthy controls (HC; n =58) who were negative for p.G2385R and p.R1628P. Exclusion criteria included recent acute infections and inability to complete assessments. Exposure: PD with and without LRRK2 p.G2385R/p.R1628P risk variants. Main Outcomes and Measures: pRab10 Thr73 and pLRRK2 Ser935 phosphorylation were measured using multiplexed quantitative immunoblotting. Clinical severity was evaluated using standardized MDS-UPDRS, CISI-PD, and MoCA ratings. Results: Compared to HC, pRab10 Thr73 phosphorylation was significantly elevated in PD-G2385R (∼1.2-fold, p =0.011) and markedly higher in double-variant carriers (∼2.8-fold, p =0.008), but not in PD-R1628P or iPD. In parallel, pLRRK2 Ser935 phosphorylation was reduced in all PD subgroups (lowest in double-variant carriers) vs. HC, and inversely correlated with pRab10 Thr73 ( r s =-0.611, p <0.001). All double-variant carriers, the majority of single-variant carriers, and one-third of iPD exceeded the HC median in pRab10 Thr73 phosphorylation. Higher pRab10 Thr73 levels correlated with better cognition, but motor or disability associations were not significant after covariate adjustment. Conclusions and Relevance: LRRK2 kinase activity is enhanced in PD patients with LRRK2 p.G2385R, with more pronounced effects in those who carry concomitant p.R1628P variant. Elevated kinase activity in a considerable subset of iPD underscores the broader relevance of LRRK2 signaling and therapeutics beyond coding variants. The observed inter-individual variability highlights the role of additional genetic and environmental modifiers and supports biochemical stratification beyond genotyping in future LRRK2 trials.

14 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TTTzi Shin Toh
Tzi Shin Toh
HDHans Xing Ding
Hans Xing Ding
AAAnis Nadhirah Khairul Anuar
Anis Nadhirah Khairul Anuar
NZNurul Syuhada Zulhaimi
Nurul Syuhada Zulhaimi
JHJia Wei Hor
Jia Wei Hor
ATAi Huey Tan
Ai Huey Tan
LRRK2 is implicated in Parkinson’s disease (PD) microbiome–gut–brain axis. We compared plasma lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14), markers of gut permeability and endotoxin exposure, in PD patients with/without LRRK2 p.G2385R and/or p.R1628P, and controls, and examined their associations with systemic inflammation and clinical severity. Neither marker differed between groups. Across PD patients, LBP correlated with higher IL-6, TNF-α and worse motor function, while sCD14 correlated with higher IL-6, CCL5 and worse constipation. These findings highlight the clinical relevance of endotoxin-related immune signaling in PD, without LRRK2 risk variant-specific associations and identify LBP as an emerging marker of inflammatory burden.